medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2014, Number 612

<< Back Next >>

Rev Med Cos Cen 2014; 71 (612)

Síndrome de dolor miofascial, diagnóstico y tratamiento

Chavarría SJ

Language: Spanish
References: 18
Page: 683-689
PDF size: 243.11 Kb.


ABSTRACT

Myofascial pain syndrome (MFS) is one of the most common causes of chronic musculoskeletal pain. It is a non-inflammatory disorder of muscle origin located in a muscle or muscle group, which is characterized by pain in the corresponding muscle, more referred pain and the presence of a tension band, painful and increased consistency, which identifies the palpation. This band is the trigger point (PG) or trigger point. Factors such as acute trauma, repetitive microtrauma, lack of exercise, poor posture and maintained, vitamin deficiencies, sleep disorders and joint problems predispose to trigger points. The etiology of trigger points PG is due to dysfunction of the product endplate this abnormal depolarization. SMF patients with active PG trigger points have persistent localized or regional pain mainly affecting the muscles of the neck, shoulders and pelvic girdle. Sometimes may be associated with autonomic symptoms. The diagnosis is based on an adequate and thorough physical examination as well as a detailed and comprehensive history. The diagnostic criteria applied in the diagnosis are painful nodule in the taut band, recognition of pain by the patient, the characteristic pattern of referred pain and jump jump sign or sign. Treatment is pharmacologic and nonpharmacologic. This should be individualized and multidimensional, and depends on the intensity and duration of pain.


REFERENCES

  1. Chul Won Moon. Myofascial Pain Syndrome. J Korean Pain Soc. 2004; 17 (Suppl):S36-S44

  2. Davidoff R. Trigger points and myofascial pain: toward understanding how they affect headaches. Cephalalgia. 1998; Vol 18, Issue 7, 436–448.

  3. Estévez Rivera E. A. Dolor miofascial. MediUnab. 2001; Vol. 4 Número 12. 161-165.

  4. Fenollosa P, de Barutell C et al. Toxina botulínica A (Dysport®) asociada a rehabilitación, en pacientes con dolor miofascial cervical o dorsal primario: un estudio piloto multicéntrico aleatorizado. Rehabilitación. 2011; 45(2):139- 147.

  5. Fishbain D et al. Clonazepam Open Clinical Treatment Trial for Myofascial Syndrome Associated Chronic Pain. Pain Medicine. 2000; Vol 1, Issue 4, 332–339.

  6. García Franco M, Climent Barbera J, et al. Estudio comparativo de dos técnicas de infiltración miofascial en puntos gatillo: punción seca e inyección de anestésico local. Rehabilitación. 2006; 40(4):188-92.

  7. Gerwin R. D. Classification, epidemiology, and natural history of myofascial pain syndrome. Current Pain and Headache Reports. 2001; Vol 5, Issue 5, 412-420.

  8. Göbel Hartmut et al. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport®) for the relief of upper back myofascial pain syndrome: Results from a randomized doubleblind placebo-controlled multicentre study. PAIN. 2006; Vol 125, Issue 1; 82-88.

  9. González M. J; García M. E. Síndromes de Dolor Miofascial y Fibromialgia. Anestesia en México. 2005; Vol.17, Suplemento 1.

  10. Hernández Felix M. F. Síndromes miofasciales. Reumatol Clin. 2009; Vol. 05 Núm.Extra 2. 05:36-9.

  11. Insausti J, Djibilian R et al. Técnicas en dolor miofascial. Toxina botulínica. Rev. Soc. Esp. Dolor. 2011; 18(6): 361-365.

  12. Insausti Valdivia J. Dolor miofascial, manual de exploración y tratamiento. Ergon, España. 2006.

  13. Itza F, Zarza D, et al. Síndrome de dolor miofascial del suelo pélvico: una patóloga urológica muy frecuente. Actas Urol Esp. 2010; 34 (4) : 318–326.

  14. Kamanli A. et al. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatology International. October 2005; Vol 25, Issue 8, 604- 611.

  15. Lin-Fen Hsieh et al. Efficacy and Side Effects of Diclofenac Patch in Treatment of Patients with Myofascial Pain Syndrome of the Upper Trapezius. Journal of Pain and Symptom Management. 2010; Vol 39, Issue 1, 116-125.

  16. Ruiz M et al. Dolor de origen muscular: dolor miofascial y fibromialgia. Rev. Soc. Esp. Dolor. 2007; Vol. 14, n.1 Narón; 36-44.

  17. Torres Huerta J, Hernández Santos J et al. Toxina botulínica tipo A para el manejo del dolor en pacientes con síndrome de dolor miofascial crónico. Rev Soc Esp Dolor. 2010;17(1): 22-27.

  18. Zuil Escobar J. C, García del Pozo M, González Propin M. Modificaciones del umbral de dolor en un punto gatillo miofascial tras técnica de energía muscular. Rev Soc Esp Dolor. 2010; 17(7):313–319.




2020     |     www.medigraphic.com